PTCT Stock Summary and Trading Ideas (PTC Therapeutics | NASDAQ:PTCT)

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics trades on the NASDAQ stock market under the symbol PTCT.

As of April 18, 2024, PTCT stock price declined to $24.69 with 780,540 million shares trading.

PTCT has a beta of 1.49, meaning it tends to be more sensitive to market movements. PTCT has a correlation of 0.06 to the broad based SPY ETF.

PTCT has a market cap of $1.86 billion. This is considered a Small Cap stock.

Last quarter PTC Therapeutics reported $307 million in Revenue and -$.24 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.74.

In the last 3 years, PTCT stock traded as high as $59.84 and as low as $17.53.

The top ETF exchange traded funds that PTCT belongs to (by Net Assets): VTI, XBI, VB, IWM, FBT.

PTCT has underperformed the market in the last year with a price return of -53.4% while the SPY ETF gained +22.2%. PTCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.7% and -11.3%, respectively, while the SPY returned +5.2% and -2.6%, respectively.

PTCT support price is $24.33 and resistance is $25.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTCT stock will trade within this expected range on the day.